In vitro activity of new rifamycins aganst rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria

  • Dickinson J
  • Mitchison D
  • 5

    Readers

    Mendeley users who have this article in their library.
  • 54

    Citations

    Citations of this article.

Abstract

Comparisons were made of the in vitro activity of rifampicin, and the rifamycin derivatives, rifapentine, rifabutin, CGP 29861, CGP 7040 and CGP 27557, against rifampicin-sensitive and rifampicin-resistant strains of Mycobacterium tuberculosis and against the Mycobacterium avium/intracellulare/scrofulaceum (MAIS) complex. The new rifamycins had MICs four to eight times lower than those of rifampicin against sensitive M. tuberculosis strains. Of the 35 rifampicin-resistant strains of M. tuberculosis 31% were sensitive to rifabutin but only 3-11% to the other rifamycins. The proportions of the MAIS strains found to be sensitive were 35% for rifapentine and rifabutin and 85-92% for CGP 29861 and CGP 7040. © 1987.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Jean M. Dickinson

  • D. A. Mitchison

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free